Tibotec’s long-awaited, well-studied protease inhibitor (PI) TMC114will be in expanded access this fall (www.tibotec.com will have detailssoon). The PI boasts a resistance pattern all its own, holdinghope for those who’ve run out of PIs. Boosted with  Norvir andpaired with a med to which you’re not resistant—like entry inhibitorFuzeon—it promises to lower rising viral loads. Expect FDA approval of114 in ’06.